2.71 USD
+0.04 (+1.5%)
2.71 USD
0 (0%)
Overall CATX gets a fundamental rating of 2 out of 10. We evaluated CATX against 525 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. CATX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year CATX has reported negative net income.
- In the past year CATX has reported a negative cash flow from operations.
- In the past 5 years CATX always reported negative net income.
- CATX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CATX has a Return On Assets of -35.89%. This is in the better half of the industry: CATX outperforms 61.71% of its industry peers.
- CATX has a Return On Equity of -43.68%. This is in the better half of the industry: CATX outperforms 69.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.89% | ||
| ROE | -43.68% | ||
| ROIC | N/A |
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CATX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CATX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CATX has more shares outstanding
- Compared to 1 year ago, CATX has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.44, we must say that CATX is in the distress zone and has some risk of bankruptcy.
- CATX has a better Altman-Z score (0.44) than 61.71% of its industry peers.
- A Debt/Equity ratio of 0.01 indicates that CATX is not too dependend on debt financing.
- The Debt to Equity ratio of CATX (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.44 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- CATX has a Current Ratio of 8.66. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
- CATX has a Current ratio of 8.66. This is in the better half of the industry: CATX outperforms 76.57% of its industry peers.
- CATX has a Quick Ratio of 8.66. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
- CATX has a better Quick ratio (8.66) than 76.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.66 | ||
| Quick Ratio | 8.66 |
3. Growth
3.1 Past
- CATX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.45%, which is quite impressive.
- CATX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.50%.
- CATX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -27.60% yearly.
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-59.5%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%
3.2 Future
- Based on estimates for the next years, CATX will show a decrease in Earnings Per Share. The EPS will decrease by -3.65% on average per year.
- The Revenue is expected to grow by 189.01% on average over the next years. This is a very strong growth
EPS Next Y-50.76%
EPS Next 2Y-25.94%
EPS Next 3Y-11.94%
EPS Next 5Y-3.65%
Revenue Next Year-18.33%
Revenue Next 2Y-19.35%
Revenue Next 3Y-23.12%
Revenue Next 5Y189.01%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CATX. In the last year negative earnings were reported.
- Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as CATX's earnings are expected to decrease with -11.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.94%
EPS Next 3Y-11.94%
5. Dividend
5.1 Amount
- CATX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PERSPECTIVE THERAPEUTICS INC / CATX FAQ
Can you provide the ChartMill fundamental rating for PERSPECTIVE THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to CATX.
Can you provide the valuation status for PERSPECTIVE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to PERSPECTIVE THERAPEUTICS INC (CATX). This can be considered as Overvalued.
How profitable is PERSPECTIVE THERAPEUTICS INC (CATX) stock?
PERSPECTIVE THERAPEUTICS INC (CATX) has a profitability rating of 1 / 10.
How sustainable is the dividend of PERSPECTIVE THERAPEUTICS INC (CATX) stock?
The dividend rating of PERSPECTIVE THERAPEUTICS INC (CATX) is 0 / 10 and the dividend payout ratio is 0%.